Broader solid tumor studies corroborate that pharmacological inhibition of CAF-mediated Gln synthesis disrupts tumor metabolic fitness, suggesting combinatorial targeting of tumoral and stromal glutamine metabolism, particularly through dual GLS1/ECM pathway inhibition, may offer promising therapeutic avenues for advanced prostate cancer (196). This evidence concerns the gene GLS and neoplasm.